X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (34) 34
index medicus (26) 26
humans (22) 22
pharmacology & pharmacy (19) 19
phenazines - pharmacokinetics (18) 18
phenazines - pharmacology (16) 16
biochemistry & molecular biology (13) 13
phenazines (13) 13
phenazines - chemistry (12) 12
male (11) 11
mice (11) 11
female (10) 10
microbiology (9) 9
phenazine (9) 9
cancer (8) 8
oncology (8) 8
chemistry, medicinal (7) 7
molecular structure (7) 7
pharmacokinetics (7) 7
phenazines - metabolism (7) 7
phenazines - toxicity (7) 7
rats (7) 7
biosynthesis (6) 6
clofazimine (6) 6
drugs (6) 6
in-vitro (6) 6
microbial sensitivity tests (6) 6
structure-activity relationship (6) 6
antibiotics (5) 5
cell survival - drug effects (5) 5
cytotoxicity (5) 5
dna (5) 5
mycobacterium tuberculosis - drug effects (5) 5
rabbits (5) 5
time factors (5) 5
administration, oral (4) 4
analysis (4) 4
antineoplastic agents - pharmacology (4) 4
antitubercular agents - pharmacology (4) 4
bacteria - genetics (4) 4
bacteria - metabolism (4) 4
biophysics (4) 4
biotechnology (4) 4
cattle (4) 4
cells, cultured (4) 4
chemistry, multidisciplinary (4) 4
chemistry, organic (4) 4
cinnolines (4) 4
clofazimine - pharmacology (4) 4
fused nitrogen heterocycles (4) 4
inhibition (4) 4
metabolism (4) 4
mycobacterium-tuberculosis (4) 4
phenazines - chemical synthesis (4) 4
phthalazines (4) 4
pteridines (4) 4
pyrazines (4) 4
pyridazines (4) 4
quinazolines (4) 4
quinoxalines (4) 4
tetramethylpiperidine-substituted phenazines (4) 4
acute renal failure (3) 3
adenosine triphosphate - metabolism (3) 3
adult (3) 3
aged (3) 3
anti-bacterial agents - therapeutic use (3) 3
antitubercular agents - pharmacokinetics (3) 3
antituberculosis activity (3) 3
antitumor-activity (3) 3
article (3) 3
bacteria (3) 3
biochemistry, general (3) 3
biomedicine (3) 3
biotechnology & applied microbiology (3) 3
cell line, tumor (3) 3
chemical synthesis (3) 3
chemistry (3) 3
chemotherapy (3) 3
circular dichroism (3) 3
clofazimine - pharmacokinetics (3) 3
clofazimine - therapeutic use (3) 3
coloring agents - pharmacokinetics (3) 3
derivatives (3) 3
disease models, animal (3) 3
drug delivery systems (3) 3
drug resistance, multiple (3) 3
drug stability (3) 3
heterocyclic compounds (3) 3
infectious diseases (3) 3
inhibitory concentration 50 (3) 3
kidney (3) 3
kidney tubules, proximal - metabolism (3) 3
maximum tolerated dose (3) 3
mice, nude (3) 3
middle aged (3) 3
mycobacterium tuberculosis (3) 3
nanoparticles (3) 3
oxidation-reduction (3) 3
pharmacology/toxicology (3) 3
physiology (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
British Journal of Cancer, ISSN 0007-0920, 10/2007, Volume 97, Issue 7, pp. 844 - 850
The bis-phenazine XR5944.14 is a novel cytotoxic agent which intercalates into DNA and inhibits transcription. The objectives of this study were to determine... 
Solid tumours | XR5944.14 | Phase I | solid tumours | MLN944 | VIVO | ONCOLOGY | phase I | ANTITUMOR-ACTIVITY | COMBINATION | Maximum Tolerated Dose | Phenazines - pharmacokinetics | Area Under Curve | Humans | Middle Aged | Adult | Female | Male | Aged | Infusions, Intravenous | Phenazines - toxicity | Neoplasms - drug therapy | Clinical Studies
Journal Article
Journal Article
Crystal Growth & Design, ISSN 1528-7483, 12/2016, Volume 16, Issue 12, pp. 7240 - 7250
Clofazimine is an anti-mycobacterial agent used as part of a multidrug treatment for leprosy. Recently clofazimine has shown promising activity against... 
EFFICACY | CYCLODEXTRIN | MATERIALS SCIENCE, MULTIDISCIPLINARY | SUBSTITUTED PHENAZINES | CRYSTAL | CRYSTALLOGRAPHY | CHEMISTRY, MULTIDISCIPLINARY | SOLUBILITY | ACCURACY | FORMS | IN-VITRO | ANTITUBERCULOSIS ACTIVITY | PHARMACOKINETICS
Journal Article
Current radiopharmaceuticals, 2015, Volume 8, Issue 1, p. 56
The aim of this study was to investigate the capability of phenazine dioxides, recognized bioreductive antitumour agents, as carriers for (99m)Tc in order to... 
Cell Hypoxia | Technetium - pharmacokinetics | Tissue Distribution | Animals | Radiopharmaceuticals - pharmacokinetics | Phenazines - pharmacokinetics | Radionuclide Imaging | Lung Neoplasms - diagnostic imaging | Mice | Hypoxia - diagnostic imaging | Disease Models, Animal
Journal Article
Anti-Cancer Drugs, ISSN 0959-4973, 01/2002, Volume 13, Issue 1, pp. 15 - 28
XR11576, a novel phenazine, was developed as an inhibitor of both topoisomerase I and II. This study characterized the ability of XR11576 to inhibit both... 
Dual topoisomerase I and II poison | XR11576 | Antitumor agent | Pharmacokinetics | dual topoisomerase I and II poison | DRUG | MEDIATED MULTIDRUG-RESISTANCE | ANTITUMOR-ACTIVITY | COLON-CANCER | TAS-103 | ACLARUBICIN | N-<2-(DIMETHYLAMINO)ETHYL>ACRIDINE-4-CARBOXAMIDE | ONCOLOGY | pharmacokinetics | antitumor agent | PHARMACOLOGY & PHARMACY | DNA TOPOISOMERASES | CELL-CYCLE | ORIGINAL MECHANISM | Injections, Intravenous | Rats, Wistar | Drug Resistance, Multiple | Colonic Neoplasms - drug therapy | Humans | ATP-Binding Cassette, Sub-Family B, Member 1 - metabolism | Neoplasms, Experimental - enzymology | Topoisomerase I Inhibitors | Body Weight - drug effects | Drug Resistance, Neoplasm | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Enzyme Inhibitors - administration & dosage | Neoplasms, Experimental - pathology | Tissue Distribution | Enzyme Inhibitors - pharmacokinetics | Topoisomerase II Inhibitors | Female | Antineoplastic Agents - pharmacokinetics | Cell Survival - drug effects | Phenazines - administration & dosage | Phenazines - therapeutic use | Phenazines - pharmacokinetics | Administration, Oral | Tumor Cells, Cultured - drug effects | Rats | Enzyme Inhibitors - therapeutic use | Maximum Tolerated Dose | Animals | Mice, Nude | Colonic Neoplasms - enzymology | Mice | Mice, Inbred BALB C | Neoplasms, Experimental - drug therapy
Journal Article
Journal of the American Society of Nephrology, ISSN 1046-6673, 2005, Volume 16, Issue 6, pp. 1742 - 1751
Journal Article
Journal Article